Coronavirus vaccine - summary of Yellow Card reporting (up to 14 April)

Up to 14 April, the MHRA received reports of 168 cases of major thromboembolic events with concurrent thrombocytopenia following vaccination with the AstraZeneca Covid-19 vaccine (incidence of 7.9 per million doses), including 77 cases of cerebral venous sinus thrombosis.

SPS commentary:

The data suggest there is a higher incidence reported in the younger adult age groups and the MHRA advises that this evolving evidence should be taken into account when considering the use of the vaccine. On the basis of an ongoing review, the advice remains that the benefits of the vaccine outweigh the risks in the majority of people.

Medicines and Healthcare products Regulatory Agency